股市特别报道丨诺泰生物财务造假将被ST 招商基金等公募或踩雷

Core Viewpoint - Notai Bio has been suspended from trading due to financial fraud, with its stock being relisted under the risk warning designation "ST Notai" starting July 22, following a one-day suspension on July 21 [1][2]. Company Summary - Notai Bio received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for false reporting in its 2021 annual report, which inflated revenue by 30 million yuan and net profit by 25.9516 million yuan [1]. - The company faces a fine of 47.4 million yuan and its actual controller, Zhao Dezhong, is fined 13 million yuan, with other responsible parties also facing penalties [1]. - The board of directors is taking the risk warning seriously and plans to implement measures to mitigate the impact of these issues [2]. Shareholding Situation - Major public fund managers, including China Merchants Fund, hold significant shares in Notai Bio, with a total holding value exceeding 340 million yuan as of mid-2023 [4]. - China Merchants Fund alone holds 773.05 million shares, representing 2.46% of Notai Bio's circulating A-shares [3][4]. - Specific funds managed by China Merchants have seen varying degrees of increase in their holdings, indicating potential exposure to losses if the situation worsens [4]. Industry Context - The implementation of new regulations and stricter oversight is accelerating the delisting process for companies, raising the stakes for public funds in managing risks associated with ST stocks [5]. - Public funds are urged to enhance their stock selection capabilities to navigate market changes effectively, especially in light of the increased likelihood of delistings [5].